{
  "docId": "019de075-7d9e-72c3-b72b-f46b67767727",
  "docSlug": "53c1bfc711678d7524a7d4316a5473e9",
  "documentTitle": "Chimerix | Investor Presentation Deck | 43 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 43,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The chart shows a clear dose-response/timing-response relationship where earlier treatment leads to lower viral titers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7d9e-72c3-b72b-f46b67767727/39",
  "deckHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727",
  "deckJsonHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727.json",
  "deckAnchorHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.085,
        "w": 0.668,
        "x": 0.065,
        "y": 0.76
      },
      "kind": "callout",
      "text": "$2 million grant to fund prodrug formulations that could enable oral administration with improved lung delivery",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b37edc5-e1c6-4606-94e4-a6bfcd547d99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.295,
        "x": 0.675,
        "y": 0.165
      },
      "kind": "chart",
      "text": "Viral Lung Titer Replicating SARS-COV-2-MA10",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71f2fb08-2525-49c9-aa56-f1898bbf5061",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.62,
        "x": 0.105,
        "y": 0.935
      },
      "kind": "disclaimer",
      "text": "1. Replicates lung pathology of human infection 4-days post-infection. One day in mouse is 5-7 days in humans (adjusted disease course).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6da2bdc1-18c1-4bd9-b97f-df559e909bcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.465,
        "w": 0.605,
        "x": 0.065,
        "y": 0.215
      },
      "kind": "list",
      "text": "Ribonucleoside analog that is a viral polymerase inhibitor\nInhaled nebulized liquid aerosol formulation; minimal systemic exposure\nMonotherapy efficacy in mouse-adapted SARS-CoV-2-MA10 model across multiple endpoints\nLung viral titer\nViral RNA parallel viral lung titer (plaque forming unit)\nClinical scoring (animal health)\nLung pathology\nAnimal weight loss",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3f4b211-3898-4534-b26f-5ade923c0bb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.522,
        "x": 0.239,
        "y": 0.065
      },
      "kind": "title",
      "text": "CMX-521: anti-SARS-CoV-2 preclinical activity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "580b2104-772f-4c28-a101-cb9274e7a106",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 43,
      "from": 16,
      "beatId": "159a3ef0-298f-499a-afc1-676405bbdbe9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents ONC201 as a solution, including its mechanism of action, market opportunity, and development plans",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 43,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "cb576a48-1f93-4d7c-8d9b-075787961712",
      "evidence": "The deck presents ONC201's potential for efficacy and market opportunity",
      "position": 1,
      "objective": "Can ONC201 be a quick win and a big bet for Chimerix?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}